DGIdb - PALIFERMIN Drug Record

PALIFERMIN chembl:CHEMBL1201821 Approved

Alternate Names:

KEPIVANCE
PALIFERMIN
FGF-7
HBGF-7
KERATINOCYTE GROWTH FACTOR PRECURSOR
KGF
FIBROBLAST GROWTH FACTOR- 7
rxcui:196319
chemidplus:162394-19-6
drugbank:00039
chembl:CHEMBL1201821

Drug Info:

FDA Approval	approved
Drug Class	recombinant protein
Drug Indications	for treatment of antineoplasty-induced oral mucositis
Drug Class	antimucositis agents
Year of Approval	2004

(1 More Sources)

Publications:

Matsubara et al., 1999, Hormone Refractory Prostate Cancer and Fibroblast Growth Factor Receptor., Breast Cancer
Sher et al., 2000, Identification of residues important both for primary receptor binding and specificity in fibroblast growth factor-7., J. Biol. Chem.
Wang et al., 1999, Common and specific determinants for fibroblast growth factors in the ectodomain of the receptor kinase complex., Biochemistry
Ostrovsky et al., 2002, Differential effects of heparin saccharides on the formation of specific fibroblast growth factor (FGF) and FGF receptor complexes., J. Biol. Chem.
Lu et al., 1999, Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate., J. Biol. Chem.
Beer et al., 2000, Fibroblast growth factor (FGF) receptor 1-IIIb is a naturally occurring functional receptor for FGFs that is preferentially expressed in the skin and the brain., J. Biol. Chem.
Cancilla et al., 2001, Fibroblast growth factor receptors and their ligands in the adult rat kidney., Kidney Int.
Launay et al., 1994, Comparative analysis of the tissue distribution of three fibroblast growth factor receptor mRNAs during amphibian morphogenesis., Differentiation
Mummery et al., 1993, Fibroblast growth factor-mediated growth regulation and receptor expression in embryonal carcinoma and embryonic stem cells and human germ cell tumours., Biochem. Biophys. Res. Commun.
Yamanaka et al., 2000, Isolation and serum-free culture of epithelial cells derived from epithelial rests of Malassez in human periodontal ligament., In Vitro Cell. Dev. Biol. Anim.
Imagawa et al., 1994, Keratinocyte growth factor and acidic fibroblast growth factor are mitogens for primary cultures of mammary epithelium., Biochem. Biophys. Res. Commun.
Sannes et al., 1998, Sulfation of extracellular matrices modifies growth factor effects on type II cells on laminin substrata., Am. J. Physiol.
Luo et al., 1998, The glycine box: a determinant of specificity for fibroblast growth factor., Biochemistry
Patrie et al., 1995, Conservation of ligand specificity between the mammalian and amphibian fibroblast growth factor receptors., J. Biol. Chem.
Zhu et al., 2007, Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells., Am. J. Pathol.
Beaven et al., 2007, Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant., Drugs Today
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Radtke et al., 2005, Palifermin (Kepivance) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support., J Oncol Pharm Pract
Cardoso et al., 1997, FGF-1 and FGF-7 induce distinct patterns of growth and differentiation in embryonic lung epithelium., Dev. Dyn.
Huang et al., 2006, Effect of keratinocyte growth factor on cell viability in primary cultured human prostate cancer stromal cells., J. Steroid Biochem. Mol. Biol.
Berman et al., 1999, Similarities and differences between the effects of heparin and glypican-1 on the bioactivity of acidic fibroblast growth factor and the keratinocyte growth factor., J. Biol. Chem.
Friedl et al., 1997, Differential binding of fibroblast growth factor-2 and -7 to basement membrane heparan sulfate: comparison of normal and abnormal human tissues., Am. J. Pathol.
Iwabuchi et al., 2006, Syndecan-4 dependent FGF stimulation of mouse vibrissae growth., Mech. Dev.
Sharma et al., 1998, Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo., J. Clin. Invest.
Asada et al., Expression of fibroblast growth factor receptor genes in human hepatoma-derived cell lines., In Vitro Cell. Dev. Biol. Anim.

PALIFERMIN HSPG2

Interaction Score: 17.17

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name rHu-KGF, keratinocyte growth factor (KGF),Kepivance

Novel drug target Established target

PMIDs:
16989989 9788974 14753849 10593896

Sources:
TdgClinicalTrial
PALIFERMIN NRP1

Interaction Score: 13.74

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name rHu-KGF, keratinocyte growth factor (KGF),Kepivance

Novel drug target Established target

PMIDs:
9094999 9890894 10821861

Sources:
TdgClinicalTrial
PALIFERMIN FGFR4

Interaction Score: 2.77

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name rHu-KGF, keratinocyte growth factor (KGF),Kepivance

Novel drug target Established target

PMIDs:
7526860 10950949 9755102 11149756 9843417

Sources:
TdgClinicalTrial TEND
PALIFERMIN FGFR2

Interaction Score: 2.42

Interaction Types & Directionality:

agonist (activating)

binder

Interaction Info:

Trial Name rHu-KGF, keratinocyte growth factor (KGF),Kepivance

Novel drug target Established target

Mechanism of Interaction Fibroblast growth factor receptor 2 agonist

PMIDs:
7499435 17456767 17728847 11752352 16390600 9056643 16854582 10593896

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD
PALIFERMIN FGFR3

Interaction Score: 1.16

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name rHu-KGF, keratinocyte growth factor (KGF),Kepivance

Novel drug target Established target

PMIDs:
10821861 11422746 7890137 7680555 11149756

Sources:
TdgClinicalTrial TEND
PALIFERMIN FGFR1

Interaction Score: 0.73

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name rHu-KGF, keratinocyte growth factor (KGF),Kepivance

Novel drug target Established target

PMIDs:
11091737 10950949 9890894 11714710 10212269

Sources:
TdgClinicalTrial

TEND: PALIFERMIN
- Version: 01-August-2011
Alternate Names:

PALIFERMIN Primary Drug Name

Drug Info:

Year of Approval 2004

Drug Class antimucositis agents

Publications:
TdgClinicalTrial: PALIFERMIN
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications for treatment of antineoplasty-induced oral mucositis

Drug Class recombinant protein

FDA Approval approved

Publications:
TTD: Palifermin
- Version: 2020.06.01
Alternate Names:

D0O7GU TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1201821
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1201821
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Trial Name	rHu-KGF, keratinocyte growth factor (KGF),Kepivance
Novel drug target	Established target

agonist (activating)
binder

PALIFERMIN Drug Record

PALIFERMIN chembl:CHEMBL1201821 Approved

Alternate Names:

Drug Info:

Publications:

PALIFERMIN HSPG2

Interaction Types & Directionality: n/a

Interaction Info: Trial Name rHu-KGF, keratinocyte growth factor (KGF),Kepivance Novel drug target Established target

PMIDs: 16989989 9788974 14753849 10593896

Sources: TdgClinicalTrial

PALIFERMIN NRP1

Interaction Types & Directionality: n/a

Interaction Info: Trial Name rHu-KGF, keratinocyte growth factor (KGF),Kepivance Novel drug target Established target

PMIDs: 9094999 9890894 10821861

Sources: TdgClinicalTrial

PALIFERMIN FGFR4

Interaction Types & Directionality: n/a

Interaction Info: Trial Name rHu-KGF, keratinocyte growth factor (KGF),Kepivance Novel drug target Established target

PMIDs: 7526860 10950949 9755102 11149756 9843417

Sources: TdgClinicalTrial TEND

PALIFERMIN FGFR2

Interaction Types & Directionality: agonist (activating) binder

Interaction Info: Trial Name rHu-KGF, keratinocyte growth factor (KGF),Kepivance Novel drug target Established target Mechanism of Interaction Fibroblast growth factor receptor 2 agonist

PMIDs: 7499435 17456767 17728847 11752352 16390600 9056643 16854582 10593896

Sources: TdgClinicalTrial ChemblInteractions TEND TTD

PALIFERMIN FGFR3

Interaction Types & Directionality: n/a

Interaction Info: Trial Name rHu-KGF, keratinocyte growth factor (KGF),Kepivance Novel drug target Established target

PMIDs: 10821861 11422746 7890137 7680555 11149756

Sources: TdgClinicalTrial TEND

PALIFERMIN FGFR1

Interaction Types & Directionality: n/a

Interaction Info: Trial Name rHu-KGF, keratinocyte growth factor (KGF),Kepivance Novel drug target Established target

PMIDs: 11091737 10950949 9890894 11714710 10212269

Sources: TdgClinicalTrial

TEND: PALIFERMIN

Alternate Names: PALIFERMIN Primary Drug Name

Drug Info: Year of Approval 2004 Drug Class antimucositis agents

Publications:

TdgClinicalTrial: PALIFERMIN

Alternate Names:

Drug Info: Drug Indications for treatment of antineoplasty-induced oral mucositis Drug Class recombinant protein FDA Approval approved

Publications:

TTD: Palifermin

Alternate Names: D0O7GU TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1201821

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL1201821

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name rHu-KGF, keratinocyte growth factor (KGF),Kepivance

Novel drug target Established target

PMIDs:
16989989 9788974 14753849 10593896

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name rHu-KGF, keratinocyte growth factor (KGF),Kepivance

Novel drug target Established target

PMIDs:
9094999 9890894 10821861

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name rHu-KGF, keratinocyte growth factor (KGF),Kepivance

Novel drug target Established target

PMIDs:
7526860 10950949 9755102 11149756 9843417

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

agonist (activating)

binder

Interaction Info:

Trial Name rHu-KGF, keratinocyte growth factor (KGF),Kepivance

Novel drug target Established target

Mechanism of Interaction Fibroblast growth factor receptor 2 agonist

PMIDs:
7499435 17456767 17728847 11752352 16390600 9056643 16854582 10593896

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name rHu-KGF, keratinocyte growth factor (KGF),Kepivance

Novel drug target Established target

PMIDs:
10821861 11422746 7890137 7680555 11149756

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name rHu-KGF, keratinocyte growth factor (KGF),Kepivance

Novel drug target Established target

PMIDs:
11091737 10950949 9890894 11714710 10212269

Sources:
TdgClinicalTrial

Alternate Names:

PALIFERMIN Primary Drug Name

Drug Info:

Year of Approval 2004

Drug Class antimucositis agents

Drug Info:

Drug Indications for treatment of antineoplasty-induced oral mucositis

Drug Class recombinant protein

FDA Approval approved

Alternate Names:

D0O7GU TTD Drug ID